Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma(Front. Oncol., (2022), 12, (1021632), 10.3389/fonc.2022.1021632)
Issued Date
2023-01-06
Resource Type
eISSN
2234943X
Scopus ID
2-s2.0-85146757083
Journal Title
Frontiers in Oncology
Volume
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Oncology Vol.12 (2023)
Suggested Citation
Prasopporn S., Suppramote O., Ponvilawan B., Jamyuang C., Chanthercrob J., Chaiboonchoe A., More-Krong P., Kongsri K., Suntiparpluacha M., Chanwat R., Korphaisarn K., Okada S., Sampattavanich S., Jirawatnotai S. Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma(Front. Oncol., (2022), 12, (1021632), 10.3389/fonc.2022.1021632). Frontiers in Oncology Vol.12 (2023). doi:10.3389/fonc.2022.1124912 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/81688
Title
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma(Front. Oncol., (2022), 12, (1021632), 10.3389/fonc.2022.1021632)
Author's Affiliation
Other Contributor(s)
Abstract
In the published article, there was an error in the Funding statement. There was one missing funding agency from our manuscript. The correct Funding statement appears below.Funding This study was funded by grants from the National Science and Technology Development Agency (NSTDA) of Thailand, the Japan Science and Technology Agency, and the National Institute of Allergy and Infectious Diseases of the United States as part of the e-ASIA Joint Research Program (e-ASIA JRP); the NSTDA (P-15- 50208), the National Research Council of Thailand (NRCT) R016441034, the Advanced Research in Pharmacology Fund, Siriraj Foundation (D003421), and by Mahidol University (Basic Research Fund, and the grant of fiscal year 2022). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.